BL PharmTech

BL PharmTech EBITDA per Share

The EBITDA per Share of BL PharmTech (065170.KQ) as of Nov 6, 2026 is 0.37 KRW. In the previous year, EBITDA per Share was -70.90 KRW — a change of -100.53% (higher).

EBITDA per Share

0.37KRW

YoY

-100.53%

Last updated:

EBITDA per Share of BL PharmTech is 2025 0.37 KRW. EBITDA per Share of BL PharmTech was 2024 -70.90 KRW. It decreases by -100.53% higher compared to the previous year.

The BL PharmTech EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
33.64 KRW
Jan 1, 2019
-381.17 KRW
Jan 1, 2020
-247.22 KRW
Jan 1, 2021
-50.18 KRW
Jan 1, 2022
-127.12 KRW
Jan 1, 2023
-132.55 KRW
Jan 1, 2024
-70.90 KRW
Jan 1, 2025
0.37 KRW
The BL PharmTech EBITDA per Share history
YEAREBITDA per ShareYoY
0.37KRW-100.53%
-70.90KRW-46.51%
-132.55KRW+4.27%
-127.12KRW+153.35%
-50.18KRW-79.70%
-247.22KRW-35.14%
-381.17KRW-1,232.97%
33.64KRW-53.66%
72.61KRW+129.01%
31.70KRW-301.83%
-15.71KRW-146.12%
34.06KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BL PharmTech Stock analysis

What does BL PharmTech do? BL PharmTech Corp generates revenue through four business segments. The Health Functional Food Business segment sells red ginsengs, diet foods, and vitamins. The Cosmetics Business segment offers anti-aging skincare products. The Diagnostic and Medical Business segment provides diagnostic kits and related products. The Other segment distributes health foods and other products. Customers include consumers seeking health supplements, skincare solutions, and medical diagnostic tools. The company targets health-conscious individuals and medical professionals who purchase these specialized products. The firm's revenue streams are derived from direct sales of manufactured goods across all segments. Red ginsengs, diet foods, and vitamins are sold under the Health Functional Food Business segment. Anti-aging skincare products come from the Cosmetics Business segment. Diagnostic kits and other medical products are sold through the Diagnostic and Medical Business segment. Distribution services for health foods form the Other segment's contribution to revenue. BL PharmTech Corp's customers primarily consist of end consumers for health functional foods and cosmetics, while medical institutions purchase diagnostic kits. The company's products are distributed through retail channels and direct sales to healthcare providers. Revenue is generated from the sale of manufactured items rather than licensing or subscription models. BL PharmTech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BL PharmTech stock

EBITDA per Share of BL PharmTech is 0.37 KRW in 2025.

EBITDA per Share of BL PharmTech changed from -70.90 KRW to 0.37 KRW, representing a -100.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share BL PharmTech since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BL PharmTech

All Key Metrics — BL PharmTech